Pneumocystis jirovecii and cystic fibrosis in France

Gal, Solène Le; Héry-Arnaud, Geneviève; Ramel, Sophie; Virmaux, Michèle; Damiani, Céline; Totet, Anne; Nevez, Gilles

doi:10.3109/00365540903447000

Cited by 19 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our observations, it is a reliable technique that allowed us to detect Pneumocystis colonization in 12.5% of our patients. This percentage is in agreement with data reported for CF patients from European and Brazilian areas (7.4, 21.5, and 38.2%) (22,24,26) but higher than the value of 1.3% reported by Le Gal et al for a series of 76 CF patients from French Brittany (14). As previously reported (1,17), such geographic differences in Pneumocystis carriage prevalence might be linked with the local Pneumocystis circulation, which may be lower in northern France (14; our results in Lille).…”

supporting

confidence: 93%

“…Despite technical factors that can influence the reported prevalence of Pneumocystis colonization, and according to the abovecited studies (including our results), it appears that CF is associated with lower Pneumocystis colonization rates than are other chronic pulmonary diseases (14,20,22,24,26,27,32). Three studies have reported the association of P. jirovecii and P. aeruginosa in CF patients (14,22,25), but whether Pneumocystis infection/colonization complicated CF-associated lung disease remains unclear.…”

supporting

confidence: 46%

“…Several works support a significant association of P. jirovecii colonization with diverse chronic pulmonary diseases (6,12,21). Few severe PcP cases in cystic fibrosis (CF) patients have been reported (23,25), and only some studies have reported Pneumocystis carriage, the clinical significance of which remains practically unexplored (14,(18)(19)(20)(22)(23)(24)(25)(26). The aims of the present study were therefore to evaluate the prevalence of P. jirovecii colonization during a prospective multicenter observational study, to provide information regarding the distribution of Pneumocystis genotypes, and to explore the clinical relevance of Pneumocystis colonization among CF patients in France.…”

mentioning

confidence: 99%

“…Three studies have reported the association of P. jirovecii and P. aeruginosa in CF patients (14,22,25), but whether Pneumocystis infection/colonization complicated CF-associated lung disease remains unclear. In fact, little is known regarding the in vivo interactions between species, especially considering the bacterial and fungal community as a unique entity (lung microbiota) (8,11,31).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Prospective Multicenter Study of Pneumocystis jirovecii Colonization among Cystic Fibrosis Patients in France

et al. 2012

View full text Add to dashboard Cite

show abstract

supporting

confidence: 93%

supporting

confidence: 46%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Prospective Multicenter Study of Pneumocystis jirovecii Colonization among Cystic Fibrosis Patients in France

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The prevalence of colonization varies with the population and the underlying disease. For example, Pneumocystis colonization is detected in individuals with cystic fibrosis, and the prevalence ranges from 1% to 22% (90,253,270). Patients with interstitial lung diseases appear to have a higher prevalence of colonization, especially if they are receiving corticosteroids.…”

Section: Colonization In Animalsmentioning

confidence: 99%

Colonization by Pneumocystis jirovecii and Its Role in Disease

2012

View full text Add to dashboard Cite

SUMMARY Although the incidence of Pneumocystis pneumonia (PCP) has decreased since the introduction of combination antiretroviral therapy, it remains an important cause of disease in both HIV-infected and non-HIV-infected immunosuppressed populations. The epidemiology of PCP has shifted over the course of the HIV epidemic both from changes in HIV and PCP treatment and prevention and from changes in critical care medicine. Although less common in non-HIV-infected immunosuppressed patients, PCP is now more frequently seen due to the increasing numbers of organ transplants and development of novel immunotherapies. New diagnostic and treatment modalities are under investigation. The immune response is critical in preventing this disease but also results in lung damage, and future work may offer potential areas for vaccine development or immunomodulatory therapy. Colonization with Pneumocystis is an area of increasing clinical and research interest and may be important in development of lung diseases such as chronic obstructive pulmonary disease. In this review, we discuss current clinical and research topics in the study of Pneumocystis and highlight areas for future research.

show abstract

Pneumocystis jirovecii and Cystic Fibrosis in Brittany, France

et al. 2017

View full text Add to dashboard Cite

Pneumocystis jirovecii is a transmissible fungus with a high pulmonary tropism. The prevalence of P. jirovecii in patients with cystic fibrosis (CF) has been estimated in Germany at 7.4%, in Spain at 21.5% and in Brazil at 38.2%. Data on the prevalence of P. jirovecii in CF patients in France remain scarce, particularly in Brittany, where the prevalence of CF is high (from 1/1600 to 1/4500). Our objectives were to determine the prevalence of colonization of the airways by P. jirovecii in Brittany in CF patients monitored at the "Centre de Ressources et de Compétences de la Mucoviscidose (CRCM)" of Rennes compared to that previously observed at the CRCM of Roscoff-Brest. Sputa from 86 patients (178 specimens) followed in Rennes were analyzed retrospectively. The detection of P. jirovecii was performed using real-time PCR targeting the gene encoding the mitochondrial large subunit of ribosomal RNA. Pneumocystis jirovecii DNA was detected in 3/86 patients (3.5%) monitored at Rennes, whereas it had previously been detected in 1/76 patients (1.3%) monitored at Roscoff-Brest, thus showing an overall prevalence of 2.5% in Brittany. These results obtained from two Breton centers taken together show that P. jirovecii prevalence in patients with CF in Brittany is lower than those observed in Germany, Spain, Brazil or in other regions of France. This study is a preliminary step in determining the risk factors for P. jirovecii acquisition, its epidemiological and clinical significance in CF patients through a prospective multicenter study.

show abstract

Pneumocystis jirovecii and cystic fibrosis in France

Cited by 19 publications

References 15 publications

Prospective Multicenter Study of Pneumocystis jirovecii Colonization among Cystic Fibrosis Patients in France

Prospective Multicenter Study of Pneumocystis jirovecii Colonization among Cystic Fibrosis Patients in France

Colonization by Pneumocystis jirovecii and Its Role in Disease

Pneumocystis jirovecii and Cystic Fibrosis in Brittany, France

Contact Info

Product

Resources

About